The Journal of Pediatrics
Volume 150, Issue 4 , Pages 327-328 , April 2007

Postnatal Steroids for Bronchopulmonary Dysplasia: Where Are We Now?

  • Kristi L. Watterberg, MD

      Affiliations

    • Corresponding Author InformationReprint requests: Kristi L Watterberg, MD, Dept of Pediatrics/Neonatology, MSC10 5590, 1 University of New Mexico, Albuquerque, NM 87131-0001.

References 

  1. Mammel MC, Green TP, Johnson DE, Thompson TR. Controlled trial of dexamethasone therapy in infants with bronchopulmonary dysplasia. Lancet. 1983;1:1356–1358
  2. Yeh TF, Torre JA, Rastogi A, Anyebuno MA, Pildes RS. Early postnatal dexamethasone therapy in premature infants with severe respiratory distress syndrome: a double-blind, controlled study. J Pediatr. 1990;117:273–282
  3. Walsh MC, Yao Q, Horbar JD, Carpenter JH, Lee SK, Ohlsson A. Changes in the use of postnatal steroids for bronchopulmonary dysplasia in 3 large neonatal networks. Pediatrics 2006. Available at www.pediatrics.org/cgi/doi/10.1542/peds.2006-0359. Accessed February 20, 2007.
  4. Yeh TF, Lin YJ, Huang CC, Chen YJ, Lin CH, Lin HC, et al. Early dexamethasone therapy in preterm infants: a follow-up study. Pediatrics. 1998;101:E7
  5. O’Shea TM, Kothadia JM, Klinepeter KL, Goldstein DJ, Jackson BG, Weaver RG, et al. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age. Pediatrics. 1999;104:15–21
  6. Howard E. Reductions in size and total DNA of cerebrum and cerebellum in adult mice after corticosterone treatment in infancy. Exp Neurol. 1968;22:191–208
  7. American Academy of Pediatrics Committee on Fetus and NewbornCanadian Paediatric Society Fetus and Newborn Committee. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Pediatrics. 2002;109:330–338
  8. Doyle LW, Davis PG, Morley CJ, McPhee A, Carlin JB DART study investigators. Low-dose dexamethasone facilitates extubation among chronically ventilator-dependent infants: a multicenter, international, randomized, controlled trial. Pediatrics. 2006;117:75–83
  9. Doyle LW, Halliday HL, Ehrenkranz RA, Davis PG, Sinclair JC. Impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk for chronic lung disease. Pediatrics. 2005;115:655–661
  10. Nixon PA, Washburn LK, Schechter MS, O’Shea TM. Follow-up study of a randomized controlled trial of postnatal dexamethasone therapy in very low birth weight infants: effects on pulmonary outcomes at 8 to 11 years of age. J Pediatr. 2007;150:345–350
  11. McEwen BS. The brain is an important target of adrenal steroid actions: a comparison on synthetic and natural steroids. Ann N Y Acad Sci. 1997;823:201–213
  12. Rademaker KJ, Uiterwaal CSPM, Groenendaal F, Uniken Venema MMAT, van Bel F, Beek FJ, et al. Neonatal hydrocortisone treatment: neurodevelopmental outcome and MRI at school age in preterm born children. J Pediatr. 2007;150:351–357
  13. Watterberg KL, Shaffer ML, Mishefske MJ, Leach CL, Mammel MC, Couser RJ, et al. Growth and Neurodevelopmental Outcomes After Early Low-dose Hydrocortisone Treatment in Extremely Low Birth Weight Infants. Pediatrics. 2007;in press
  14. Watterberg KL, Shaffer ML, for the PROPHET study group. Cortisol concentrations and apparent serum half-life during hydrocortisone therapy in extremely low birth weight infants. PAS 2005;57:1501. Accessed at www.pas-meeting.org. Accessed February 20, 2007.

PII: S0022-3476(06)01201-7

doi: 10.1016/j.jpeds.2006.12.041

The Journal of Pediatrics
Volume 150, Issue 4 , Pages 327-328 , April 2007

Article Tools